Immunotherapy boosts chemo in Tough-to-Treat lymphoma trial
NCT ID NCT05221645
First seen May 20, 2026 · Last updated May 25, 2026 · Updated 1 time
Summary
This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (R-ICE) helps people with diffuse large B-cell lymphoma whose cancer has come back or not responded to earlier treatment. About 65 adults will take part. The main goal is to see if the combination keeps the cancer from growing or coming back for at least one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Oxford Cancer & Haematology Centre, The Churchill Hospital
Headington, Oxford, OX3 7LE, United Kingdom
-
The Beatson West of Scotland Cancer Centre
Glasgow, Glasgow, G12 0YN, United Kingdom
Conditions
Explore the condition pages connected to this study.